Table 3.
Baseline, median (IQR) | Post-transplantation, median (IQR) | P | |
---|---|---|---|
eGFR, ml/min/1.73 m2 | 5.38 (4.29, 6.75) | 71.97 (55.08, 78.04) | 0.005 |
CRP, mg/L | 0.42 (0.34, 0.50) | 0.55 (0.37, 1.32) | 0.24 |
TC, mg/dL | 167.0 (146.0, 239.0) | 237.0 (217.25, 293.0) | 0.02 |
Triglyceride, mg/dL | 132.50 (95.25, 220.50) | 162.0 (129.0, 204.75) | 0.72 |
HDL-cholesterol, mg/dL | 36.50 (27.0, 53.50) | 55.0 (41.50, 75.50) | 0.047 |
LDL-cholesterol, mg/dL | 100.0 (88.50, 167.0) | 142.50 (133.75, 168.25) | 0.074 |
TNF-α, pg/mL | 14.95 (13.87, 18.25) | 13.42 (11.62, 16.38) | 0.45 |
Rituximab-untreated group (n=5) | 15.13 (13.60, 18.19) | 12.07 (11.16, 13.87) | 0.04 |
Rituximab-treated group (n=5) | 14.76 (13.62, 18.55) | 15.41 (12.86, 25.00) | 0.50 |
IL-6, pg/mL | 3.50 (2.67, 6.04) | 15.49 (4.12, 320.09) | 0.03 |
Rituximab-untreated group (n=5) | 3.60 (2.88, 6.18) | 5.55 (3.50, 143.01) | 0.50 |
Rituximab-treated group (n=5) | 3.16 (2.63, 4.95) | 23.33 (5.94, 655.10) | 0.04 |
PAI-1, ng/mL | 1.25 (0.94, 1.47) | 3.57 (2.59, 4.56) | 0.005 |
Rituximab-untreated group (n=5) | 1.20 (0.91, 1.41) | 4.13 (2.44, 4.65) | 0.04 |
Rituximab-treated group (n=5) | 1.29 (0.68, 1.72) | 3.10 (2.43, 4.43) | 0.04 |
Endothelin-1, pg/mL | 297.25 (253.35, 395.23) | 334.85 (280.88, 423.25) | 0.51 |
Rituximab-untreated group (n=5) | 302.20 (214.90, 377.30) | 371.30 (257.85, 441.60) | 0.23 |
Rituximab-treated group (n=5) | 292.30 (271.35, 410.05) | 311.40 (259.55, 411.10) | 0.69 |
IQR – interquartile range; eGFR – estimated glomerular filtration rate; CRP – C-reactive protein; TC – total cholesterol; HDL-C – high-density lipoprotein-cholesterol; LDL-C – low-density lipoprotein-cholesterol; TNF-α – tumor necrosis factor-alpha; IL-6 – interleukin-6; PAI-I – plasminogen activator inhibitor-1.